Table 2.
Proportion of patients with different nucleoside and non-nucleoside reverse transcriptase inhibitor regimens at the start of first-line antiretroviral therapy, by time period and region
| Central Africa | East Africa | |||||||||||||||
| 2001- 2002 |
2003- 2004 |
2005- 2006 |
2007- 2008 |
2009- 2010 |
2011- 2012 |
2013- 2014 |
2015- 2016 |
2001- 2002 |
2003- 2004 |
2005- 2006 |
2007- 2008 |
2009- 2010 |
2011- 2012 |
2013- 2014 |
2015- 2016 |
|
| No of patients | – | 927 | 2766 | 4930 | 4848 | 5574 | 6048 | 5423 | 819 | 6710 | 27 614 | 33 290 | 39 674 | 46 578 | 44 834 | 38 905 |
| NRTI | ||||||||||||||||
| FTC+TDF | – | 1.2 | 4.4 | 0.8 | 3.5 | 5.0 | 6.6 | 9.2 | 0.8 | 5.4 | 0.3 | 1.0 | 0.9 | 1.1 | 1.4 | 0.7 |
| 3TC+TDF | – | 6.4 | 4.1 | 3.9 | 34.4 | 49.7 | 60.1 | 76.5 | 2.7 | 5.0 | 1.1 | 2.3 | 9.3 | 55.1 | 77.5 | 89.7 |
| 3TC+D4T | – | 60.0 | 55.6 | 33.7 | 8.8 | 2.7 | 0.1 | 0.0 | 78.9 | 80.0 | 83.2 | 54.1 | 37.4 | 3.0 | 0.5 | 0.1 |
| 3TC+AZT | – | 29.6 | 32.7 | 54.9 | 48.6 | 35.9 | 27.0 | 6.6 | 14.0 | 9.0 | 14.8 | 41.8 | 46.4 | 35.3 | 16.6 | 6.4 |
| 3TC+ABC | – | 1.1 | 1.4 | 2.1 | 2.8 | 4.1 | 5.1 | 7.3 | 0.6 | 0.3 | 0.4 | 0.8 | 5.9 | 5.4 | 4.0 | 3.2 |
| Other | – | 1.8 | 1.8 | 4.7 | 1.9 | 2.6 | 1.1 | 0.4 | 3.1 | 0.4 | 0.2 | 0.1 | 0.2 | 0.1 | 0.0 | 0.0 |
| NNRTI | ||||||||||||||||
| NVP | – | 64.1 | 65 | 73.6 | 66.6 | 49.2 | 22.5 | 6.3 | 73.1 | 82.6 | 80.9 | 76.4 | 72.2 | 50.4 | 21.3 | 8.1 |
| EFV | – | 35.7 | 34.3 | 25.8 | 32.9 | 50.1 | 76.9 | 93.4 | 24.8 | 15.4 | 17.7 | 22.6 | 27.2 | 49.3 | 78.4 | 91.5 |
| Other | – | 0.2 | 0.7 | 0.7 | 0.5 | 0.7 | 0.6 | 0.2 | 2.0 | 2.0 | 1.4 | 1.0 | 0.6 | 0.3 | 0.4 | 0.4 |
| |
Southern Africa | West Africa | ||||||||||||||
| 2001- 2002 |
2003- 2004 |
2005- 2006 |
2007- 2008 |
2009- 2010 |
2011- 2012 |
2013- 2014 |
2015- 2016 |
2001- 2002 |
2003- 2004 |
2005- 2006 |
2007- 2008 |
2009- 2010 |
2011- 2012 |
2013- 2014 |
2015- 2016 |
|
| No. of patients | 1345 | 19 434 | 86 775 | 122 953 | 146 425 | 161 014 | 182 330 | 179 424 | 822 | 3533 | 6348 | 6490 | 7748 | 6836 | 6136 | 4451 |
| NRTI | ||||||||||||||||
| FTC+TDF | 2.0 | 0.5 | 0.5 | 17.4 | 24.9 | 34.4 | 62.2 | 51.9 | 0.6 | 0.0 | 0.1 | 1.5 | 11.5 | 17.6 | 11.5 | 11.6 |
| 3TC+TDF | 2.5 | 1.1 | 1.1 | 2.1 | 17.1 | 33.5 | 22.2 | 40.3 | 0.0 | 0.0 | 0.2 | 0.6 | 3.5 | 10.3 | 32.1 | 55.3 |
| 3TC+D4T | 37.2 | 47.7 | 55.3 | 49.5 | 36.5 | 15.3 | 3.4 | 0.2 | 39.2 | 46.8 | 51.6 | 42.6 | 21.6 | 4.8 | 0.6 | 0.0 |
| 3TC+AZT | 47.0 | 39.7 | 27.7 | 16.2 | 10.7 | 8.7 | 6.8 | 2.5 | 35.7 | 39.7 | 43.3 | 51.0 | 46.2 | 53.4 | 49.3 | 22.5 |
| 3TC+ABC | 0.7 | 0.2 | 0.3 | 1.2 | 5.0 | 6.0 | 4.9 | 5.0 | 0.2 | 0.1 | 0.4 | 0.9 | 0.9 | 4.1 | 5.8 | 10.3 |
| Other | 10.6 | 10.9 | 15.1 | 13.6 | 5.8 | 2.2 | 0.5 | 0.1 | 24.3 | 13.4 | 4.5 | 3.4 | 16.3 | 9.8 | 0.6 | 0.3 |
| NNRTI | ||||||||||||||||
| NVP | 51.1 | 58.1 | 64.8 | 55.4 | 47.2 | 36.7 | 15.6 | 3.7 | 10.1 | 12.0 | 40.9 | 46.1 | 50.2 | 47.0 | 36.1 | 15.0 |
| EFV | 43.7 | 37.8 | 31.4 | 41.5 | 50.0 | 61.2 | 82.4 | 93.9 | 50.1 | 60.6 | 46.7 | 44.4 | 39.7 | 41.5 | 53.8 | 70.7 |
| Other | 5.2 | 4.1 | 3.7 | 3.1 | 2.9 | 2.1 | 1.9 | 2.4 | 39.8 | 27.4 | 12.5 | 9.6 | 10.2 | 11.5 | 10.1 | 14.3 |
ABC, abacavir; AZT, zidovudine; D4T, stavudine; EFV, efavirenz; FTC, emtricitabine; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; NVP, nevirapine; 3TC, lamivudine; TDF, tenofovir.